Menu
X
image 12 months ago

Yescarta 2L DLBCL

Yescarta 2L DLBCL Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive types of non-Hodgkin’s lymphoma, affecting thousands of adults worldwide each year. Despite ad...

image 1 year ago

Tisagenlecleucel Mechanism of Action

Tisagenlecleucel Mechanism of Action Introduction: Revolutionizing Cancer Treatment with CAR-T Cell Therapy Tisagenlecleucel, a groundbreaking chimeric antigen receptor (CAR) T cell immunotherapy, ...

image 1 year ago

Tisagenlecleucel Follicular Lymphoma

Tisagenlecleucel Follicular Lymphoma Tisagenlecleucel, a groundbreaking CAR-T cell therapy, has shown remarkable potential in the treatment of relapsed or refractory follicular lymphoma (r/r FL). T...

image 1 year ago

Иностранные пациенты ищут лечение: Лучшая терапия CAR-T в Китае! Первый российский пациент с множественной миеломой успешно очистил опухоль и достиг CR!

**Иностранные пациенты ищут лечение: Лучшая терапия CAR-T в Китае! Первый российский пациент с множественной миеломой успешно очистил опухоль и достиг CR!** В течение пяти лет после постано...

image 1 year ago

Tisagenlecleucel FDA Approval

Tisagenlecleucel FDA Approval Tisagenlecleucel, commercially known as Kymriah, is a groundbreaking CAR-T cell therapy that has revolutionized the treatment landscape for certain types of blood canc...

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.